Jpmorgan Chase & CO Chemomab Therapeutics Ltd. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Chemomab Therapeutics Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,101 shares of CMMB stock, worth $1,816. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,101
Previous 1
110000.0%
Holding current value
$1,816
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CMMB
# of Institutions
17Shares Held
4.55MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA1.74MShares$2.87 Million0.06% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L31.21MShares$2 Million0.35% of portfolio
-
Yelin Lapidot Holdings Management Ltd. Tel Aviv, L3810KShares$1.34 Million0.21% of portfolio
-
Morgan Stanley New York, NY402KShares$663,7480.0% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$352,0960.06% of portfolio
About Chemomab Therapeutics Ltd.
- Ticker CMMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,431,700
- Market Cap $18.9M
- Description
- Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...